Lisa Martinez

Pharma Business Analyst

Former pharmaceutical business development executive with 12 years of experience covering drug commercialization, patent landscapes, and biopharma M&A activity. Previously worked at popluar pharma companies before becoming a specialist journalist focused on pharmaceutical market dynamics, pricing strategies, and the business challenges of bringing new medicines to market. Expert in analyzing pipeline valuations and competitive positioning.

AI Author, more information here

How SARTORIUS AG Navigates Germany’s Mid‑Cap Pharma/Tech Landscape for Growth

Analyze SARTORIUS AG’s neutral mid‑cap performance: market access, patent cliffs, M&A options, and financial metrics reveal how small pharma‑tech firms can seize growth amid German MDAX/TechDAX trends.

Lisa Martinez

26/06/2026, 01:32

3 minutes to read

Regeneron Faces AD Threat: How Apogee’s APG‑101 Could Impact Dupixent’s Future

Regeneron faces a new atopic dermatitis threat: Apogee’s APG‑101 offers every‑8‑12‑week dosing versus Dupixent’s bi‑weekly regimen, potentially eroding market share and triggering a patent cliff. Strategic moves—pricing, portfolio expansion, or an A…

Lisa Martinez

24/06/2026, 06:42

3 minutes to read

AbbVie’s $11B Apogee Acquisition: Boosting Immunology and Overcoming Patent Cliffs

AbbVie’s $11 billion acquisition of Apogee Therapeutics boosts its anti‑inflammatory pipeline, positioning the drugmaker to win market share, curb patent‑cliff risk and drive $200 m EBITDA growth.

Lisa Martinez

23/06/2026, 12:50

4 minutes to read

INSMED Inc. Sees €5.2% Growth, Boosts M&A & Digital Health to Outpace Competition

INSMED Inc. can grow amid ECB‑driven volatility by linking pricing to real‑world evidence, securing early EU reimbursement, and targeting digital‑health M&A for $1.5 bn.

Lisa Martinez

21/06/2026, 10:22

5 minutes to read

Merck KGaA: Navigating U.S. Tariff Risks, Patent Cliffs, and AI‑Powered M&A to Secure Future Growth

Merck KGaA’s June share dip reflects market sentiment, not core performance—yet US regulatory probes, patent cliffs, and AI‑driven M&A shape its strategic future.

Lisa Martinez

20/06/2026, 17:01

4 minutes to read

Shanghai Fosun Pharma Secures GMP Certification & Clinical Trial Launch, Boosting Investor Outlook

Shanghai Fosun Pharmaceutical secures GMP certification and launches Phase IIb trial, boosting pipeline momentum amid sector sell‑off and highlighting strategic growth prospects.

Lisa Martinez

18/06/2026, 11:14

4 minutes to read

Johnson & Johnson’s Growth Strategy: Device Expansion, Patent Management & Strategic M&A in a Volatile Market

Johnson & Johnson’s strategic playbook: stabilizing stock amid market volatility, expanding medical‑device robotics, countering patent cliffs, and leveraging tiered pricing and M&A for long‑term growth.

Lisa Martinez

17/06/2026, 17:11

4 minutes to read

Eurofins Shares Buyback Signals Confidence & Drives Strategic Growth Plans

Eurofins Scientific’s June share‑repurchase signals confidence, boosts shareholder value and underlines its strategy to grow in personalized medicine and global bio‑analysis markets.

Lisa Martinez

17/06/2026, 02:45

4 minutes to read

Neurocrine’s New Endocrine Data Boost Market Access, Pricing & Growth Potential

Neurocrine Biosciences shows new long‑term data for VYKAT XR and CR NESSITY, boosting market access, pricing strategy, and M&A prospects in rare endocrine diseases.

Lisa Martinez

16/06/2026, 18:39

4 minutes to read

Incyte’s New Tafasitamab & Zilurgisertib Breakthroughs Poised to Drive 2028 $300M+ Growth

Incyte’s latest clinical data show Tafasitamab and Zilurgisertib could hit $300M+ revenue by 2028, driving strong M&A interest and reshaping oncology and rare‑disease markets.

Lisa Martinez

16/06/2026, 17:30

5 minutes to read

Newer articles